| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Carcinoma, Islet Cell | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Adenoma, Islet Cell | |||||
| Carcinoma | |||||
| 3 | More general conditions related to this trial | ||||
| Adenocarcinoma | |||||
| Adenoma | |||||
| Digestive System Diseases | |||||
| Digestive System Neoplasms | |||||
| Endocrine Gland Neoplasms | |||||
| Endocrine System Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Pancreatic Diseases | |||||
| Pancreatic Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| sunitinib malate | |||||
| Placebo | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Sunitinib | |||||
| 6 | More general drug interventions related to this trial | ||||
| Angiogenesis Inhibitors | |||||
| Angiogenesis Modulating Agents | |||||
| Antineoplastic Agents | |||||
| Growth Inhibitors | |||||
| Growth Substances | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Pfizer | |||||
|
